Skip to main content
. 2021 Feb 1;57(2):195–203. doi: 10.1002/uog.23116

Table 2.

Clinical recommendations on thromboprophylaxis (TP) for pregnant and postpartum women with confirmed or suspected COVID‐19 (reproduced from D'Souza et al. 31 )

Isolating at home Inpatient
Low‐risk pregnancy and low risk for VTE Risk factors for VTE and not receiving TP Receiving TP Hospitalized for non‐COVID‐19‐ related reason, but asymptomatic or minor symptoms such as anosmia Pneumonia requiring supplementary oxygen but not ventilation Pneumonia requiring mechanical ventilation
Antepartum Encourage hydration and mobilization Conduct risk assessment and consider TP on individual basis Continue TP Conduct risk assessment and consider TP on individual basis Give TP (LMWH) Give TP (LMWH); dose according to local critical care protocol
Peripartum Not applicable Follow local policy for interruption of anticoagulation prior to delivery Follow local policy for interruption of anticoagulation prior to delivery Follow local policy for interruption of anticoagulation prior to delivery Follow local policy for interruption of anticoagulation prior to delivery Follow local policy for interruption of anticoagulation prior to delivery
Postpartum (while in hospital) Usual care Conduct risk assessment and consider TP on individual basis Continue usual TP Conduct risk assessment and consider TP on individual basis Give TP (LMWH) Give TP (LMWH); dose according to local critical care protocol
Postpartum (upon discharge) Usual care; encourage hydration and mobilization Usual care and consider TP on individual basis; encourage hydration and mobilization Decision based on primary indication for TP; encourage hydration and mobilization Conduct risk assessment and consider TP on individual basis; encourage hydration and mobilization Conduct risk assessment and consider extended TP on individual basis; encourage hydration and mobilization Conduct risk assessment and consider extended TP on individual basis; encourage hydration and mobilization

LMWH, low molecular weight heparin; VTE, venous thromboembolism.